A new blood test for Alzheimer's
Posted: January 8, 2011 1:52 AM PST
A team of U.S. researchers has developed a new technology that can potentially detect Alzheimer's disease with a blood test, but also other diseases, according to a study published yesterday.
"If this works with Alzheimer's disease ... it could also work with other diseases because it is a fairly broad technology platform," says Thomas Kodadek, The Scripps Research Institute in Florida (south-east ), lead author of the study published in the journal Cell. "Now we have to give this technology to specialists of various diseases for which early diagnosis is essential," he says in a statement.
There is no treatment against Alzheimer's disease - dementia the most common that affects 5 million people in the United States. Such a test could be particularly useful for pharmaceutical companies that could use it to better select patients with Alzheimer's disease for clinical trials by disease progression. This test represents a new approach for signs of disease in the blood. It used to achieve this in peptoids, synthetic molecules that can detect antibodies as immunoglobulin reacting with proteins specific to the disease.
The researchers tested this approach on mice with the equivalent of multiple sclerosis and healthy rodents. They then conducted the test on six patients suffering from Alzheimer's, Parkinson's and six of six people in good health. The authors of the study, it is also possible that one day such tests based on antibodies can detect cancer much earlier than today.
Alzheimer's French work open new perspectives
Posted: January 8, 2011 1:48 AM PST
(AFP) - There was one day
BORDEAUX - French researchers associated with American colleagues announced Thursday it had issued a finding on nerve cell receptors in the human brain, opening new therapeutic possibilities for diseases like Alzheimer's.
This brings about "chemical means" to "modify the localization of glutamate receptors", changes that appear "in some brain diseases like Alzheimer's or Huntington's disease," he told AFP Daniel Choquet Director of the Interdisciplinary Institute for Neuroscience (IINS) Bordeaux (southwest France).
The glutamate receptors are essential in transmitting information between nerve cells, and "there was previously no tool to change" their location, "he said. "With our work, we understand how the receptors are stabilized," said Choquette.
The work was conducted by the IINS, in collaboration with the Bordeaux Imaging Center (nanoscopic imaging) and a team of chemists at the Massachusetts Institute of Technology (MIT, USA).
Published Dec. 26 in Nature Chemical Biology, British scientific journal reference, the discovery opens up "new therapeutic approaches that may emerge in 5-10 years," says Daniel Choquet.
According to him, understanding the mechanisms discussed can consider the "reversibility" of the processes involved in certain brain diseases.
"The molecule we developed mimics what happens in diseases where there are problems synapses (synapses are functional areas of contact between neurons), said the scientist who proposes that this" lead molecule " can lead to a new generation of drugs.
The IINS is part of the cluster of neuroscience at the University of Bordeaux 2, a major French center for research on the brain with 45 teams representing 535 researchers, engineers and technicians.
The site of the IINS: http://www.inb.u-bordeaux2.fr/